1.8 million ED visits yearly in US 100 million lost school/work days Can develop at any age 50%...

10

Transcript of 1.8 million ED visits yearly in US 100 million lost school/work days Can develop at any age 50%...

Page 1: 1.8 million ED visits yearly in US 100 million lost school/work days Can develop at any age 50% symptomatic by age 6.
Page 2: 1.8 million ED visits yearly in US 100 million lost school/work days Can develop at any age 50% symptomatic by age 6.

1.8 million ED visits yearly in US

100 million lost school/work days

Can develop at any age50% symptomatic by age 6

Page 3: 1.8 million ED visits yearly in US 100 million lost school/work days Can develop at any age 50% symptomatic by age 6.

Pathophysiology—Complex

Airway Inflammation

Intermittent Airflow Obstruction

Bronchial Hyperresponsiveness

Page 4: 1.8 million ED visits yearly in US 100 million lost school/work days Can develop at any age 50% symptomatic by age 6.

Bronchomotor tone balance of adrenergic and cholinergic systems

Beta 2 agonists (Albuterol)◦ Direct bronchodilitation

AntiCholinergic agents (Atrovent)◦ Decreases secretions◦ Bronchodilation

Beta 1 agonists (Epinephrine)

Page 5: 1.8 million ED visits yearly in US 100 million lost school/work days Can develop at any age 50% symptomatic by age 6.

Traditional Prehospital Uses◦ Cardiac (torsades, pulseless v-fib)

◦ OB (PIH,toxemia, ecclampsia, Preterm labor)

◦ Hypomagnesemia

Page 6: 1.8 million ED visits yearly in US 100 million lost school/work days Can develop at any age 50% symptomatic by age 6.

Smooth Muscle Relaxation◦ Decreases influx at calcium channels◦ Decreases neuromuscular transmission via

decreased acetylcholine release at motor endplate

Renal Excretion

Page 7: 1.8 million ED visits yearly in US 100 million lost school/work days Can develop at any age 50% symptomatic by age 6.

Dose 2gm IV over 10 -20 min◦ Dilute in 100cc NS

Which patients benefit?◦ Prolonged, severe asthma with incomplete

response to initial therapies

How do they benefit?◦ Resolution of bronchospasm◦ Lower rates of hospitalization

Page 8: 1.8 million ED visits yearly in US 100 million lost school/work days Can develop at any age 50% symptomatic by age 6.

No Standardized Definition of “Prolonged and Severe” available for EMS

In general—pts in distress and failing to improve with standard initial therapies

Page 9: 1.8 million ED visits yearly in US 100 million lost school/work days Can develop at any age 50% symptomatic by age 6.

Side Effects:◦ CNS and respiratory depressant in BIG doses

◦ Vasodilitation – hypotension Flushing, sweating nausea

◦ Decreased contractility and heart block(Know where your CaCL is…)

Page 10: 1.8 million ED visits yearly in US 100 million lost school/work days Can develop at any age 50% symptomatic by age 6.

Who Can it Hurt?Patients on Digoxin

Patients with PreExisting Heart Block

Patients with Renal Impairment


114 M Young People (age 10-24) Arab ... - algeria.unfpa.org · including 15.5 million women of reproductive age of whom an estimated 1.5 million are pregnant. After years of protracted

114 M Young People (age 10-24) Arab ... - algeria.unfpa.org · including 15.5 million women of reproductive age of whom an estimated 1.5 million are pregnant. After years of protracted

symptomatic joint sites

symptomatic joint sites

Essential Rhythmic Palatal Tremor - NOVEL: Home · TABLE 2.' CRITERIA SEPARATING SYMPTOMATIC AND ESSENTIAL RHYTHMIC PALATAL MYOCLONUS Aetiology Neurological examination Age at onset

Essential Rhythmic Palatal Tremor - NOVEL: Home · TABLE 2.' CRITERIA SEPARATING SYMPTOMATIC AND ESSENTIAL RHYTHMIC PALATAL MYOCLONUS Aetiology Neurological examination Age at onset

18. Symptomatic Bradycardia

18. Symptomatic Bradycardia

2. STUDY PROTOCOL · BPH is nonexistent in men under age 30 but can be found in 88% of autopsied men over age 80 (Berry, 1984). Population-based prevalence estimates of symptomatic

2. STUDY PROTOCOL · BPH is nonexistent in men under age 30 but can be found in 88% of autopsied men over age 80 (Berry, 1984). Population-based prevalence estimates of symptomatic

SYMPTOMATIC TREATMENT OF FEVER

SYMPTOMATIC TREATMENT OF FEVER

Guidance on screening and symptomatic breast imaging ......Guidance on screening and symptomatic breast imaging 3 Fourth edition This fourth edition of Guidance on Screening and Symptomatic

Guidance on screening and symptomatic breast imaging ......Guidance on screening and symptomatic breast imaging 3 Fourth edition This fourth edition of Guidance on Screening and Symptomatic

8/26/2020 · 8/26/2020 6 31 32 Symptomatic thoracic disc prolapse is a rare pathology, reported to occur in 1 per million per year,2,3 accounting for 0.15–4% of all symptomatic

8/26/2020 · 8/26/2020 6 31 32 Symptomatic thoracic disc prolapse is a rare pathology, reported to occur in 1 per million per year,2,3 accounting for 0.15–4% of all symptomatic

SYMPTOMATIC CARRIERS OF HEMOPHILIA · Carrier Detection ... Symptomatic Carriers of Hemophilia 3 Table 1: Bleeding tendency in carriers, non-carriers, and an age matched group

SYMPTOMATIC CARRIERS OF HEMOPHILIA · Carrier Detection ... Symptomatic Carriers of Hemophilia 3 Table 1: Bleeding tendency in carriers, non-carriers, and an age matched group

New Horizons for Family Caregiving...• In 2012, 43.1 million adults age 65+ (13.7% of U.S. population) • By 2030, 72.7 million adults age 65+ (>20% of U.S. population) • Increasing

New Horizons for Family Caregiving...• In 2012, 43.1 million adults age 65+ (13.7% of U.S. population) • By 2030, 72.7 million adults age 65+ (>20% of U.S. population) • Increasing

Ammonites Jurasic Age approx. 146 – 200 million years old Class: Cephalopod

Ammonites Jurasic Age approx. 146 – 200 million years old Class: Cephalopod

Stone Age – the longest human age, probably began around 2.5 million years ago. - Humans used stones as tools. Stone Age – the longest human age, probably.

Stone Age – the longest human age, probably began around 2.5 million years ago. - Humans used stones as tools. Stone Age – the longest human age, probably.

AUSTRALIA’S POPULATION MAP McCrindle.pdfUNI DEGREE: 1 in 2 POP. 3.6 million 14% AGE AGE AGE AGE AGE AGE 75+ 56-74 41-55 26-40 11-25

AUSTRALIA’S POPULATION MAP McCrindle.pdfUNI DEGREE: 1 in 2 POP. 3.6 million 14% AGE AGE AGE AGE AGE AGE 75+ 56-74 41-55 26-40 11-25

What We Will Discuss...Generation Y/ 27 *75 million Nexters 1965-1980 Age: 27-41 Generation X 23 *46 million 1946-1964 Age: 42-60 Baby Boomers 30 *80 million 1922-1945 Age: 60+ *75

What We Will Discuss...Generation Y/ 27 *75 million Nexters 1965-1980 Age: 27-41 Generation X 23 *46 million 1946-1964 Age: 42-60 Baby Boomers 30 *80 million 1922-1945 Age: 60+ *75

1. Background There are over 23 million Veterans in the U.S. ~8 million Vets enrolled; 47% over age 65 Elderly Veterans are “10 years older” than age-

1. Background There are over 23 million Veterans in the U.S. ~8 million Vets enrolled; 47% over age 65 Elderly Veterans are “10 years older” than age-

SYMPTOMATIC CARRIERS OF HEMOPHILIA

SYMPTOMATIC CARRIERS OF HEMOPHILIA

for Alzheimer’s Disease Characterization of Novel CSF Tau ... · to ~16 million by 2050. Current therapeutic options are limited to symptomatic treatments highlighting the urgent

for Alzheimer’s Disease Characterization of Novel CSF Tau ... · to ~16 million by 2050. Current therapeutic options are limited to symptomatic treatments highlighting the urgent

NEXT GENERATION marketing · Age Numbers GenERATION Z < 18 50+ million Millennials 19-35 76 million Generation X 36-51 51 million baby Boomers 52-70 75 million Builders 71-88 56 million*

NEXT GENERATION marketing · Age Numbers GenERATION Z < 18 50+ million Millennials 19-35 76 million Generation X 36-51 51 million baby Boomers 52-70 75 million Builders 71-88 56 million*

9. Post MI congestive heart failure · Symptomatic CHF NYHA II Inotropes Specialized therapy Transplantation Symptomatic CHF NYHA -- IVIV Symptomatic CHF NYHA NYHA - IIIIII Pharmacotherapy

9. Post MI congestive heart failure · Symptomatic CHF NYHA II Inotropes Specialized therapy Transplantation Symptomatic CHF NYHA -- IVIV Symptomatic CHF NYHA NYHA - IIIIII Pharmacotherapy

RADIOGRAPHIC PROFILE OF SYMPTOMATIC IMPACTED …

RADIOGRAPHIC PROFILE OF SYMPTOMATIC IMPACTED …